Stage 4 bladder cancer means the cancer has grown beyond the bladder itself and spread into nearby structures, distant lymph nodes, or other organs. It is the most advanced stage and accounts for roughly 6% of all bladder cancer diagnoses. The five-year relative survival rate ranges from about 40% when spread is regional to around 9% when cancer has reached distant organs, though newer treatments are shifting those numbers.
Stage 4A vs. Stage 4B
Stage 4 is split into two substages that reflect how far the cancer has traveled. In stage 4A, the cancer has grown into the pelvic wall or abdominal wall, or it has reached lymph nodes above the major arteries in the pelvis (the common iliac arteries). The disease is still considered “locally advanced” at this point, meaning it hasn’t jumped to a completely separate part of the body.
Stage 4B means the cancer has metastasized to distant organs. Among patients with metastatic bladder cancer, the most common sites where tumors appear are lymph nodes (about 69% of patients), bone (47%), lung (37%), liver (26%), and the peritoneum, the membrane lining the abdominal cavity (16%). A person can have spread to more than one of these sites at the same time.
This distinction matters because treatment goals differ. Stage 4A cancer may still be treated aggressively with the intent to control it long term. Stage 4B treatment focuses on slowing the disease, relieving symptoms, and preserving quality of life.
Symptoms at This Stage
Early bladder cancer often shows up as blood in the urine or frequent, painful urination. By stage 4, additional symptoms typically appear that reflect where the cancer has spread. Bone pain, particularly in the back, pelvis, or hips, is common when tumors reach the skeleton. Lower back pain on one side can signal that a tumor is blocking the flow of urine from a kidney.
Many people also experience what doctors call constitutional symptoms: unexplained weight loss, loss of appetite, persistent fatigue, and general weakness. Some find they are unable to urinate at all if the tumor is compressing or blocking the urinary tract. These symptoms can overlap with many other conditions, so imaging is essential for confirming what’s happening.
How Stage 4 Is Diagnosed
Bladder cancer is initially found through cystoscopy, a procedure where a thin camera is guided into the bladder. But cystoscopy alone can’t show whether cancer has spread to lymph nodes, bones, or organs. That’s where imaging comes in.
CT scans, specifically CT urography, are the most widely used tool worldwide for staging bladder cancer. CT is particularly good at detecting cancer in lymph nodes and distant organs like the liver and lungs. MRI offers additional detail about whether the cancer has invaded the muscle wall of the bladder, which is a key factor in planning treatment. For a full-body picture, PET scans can detect metabolically active cancer cells throughout the body and are commonly used when metastatic disease is suspected or when tracking how the cancer responds to treatment.
Treatment for Locally Advanced Disease
For stage 4A bladder cancer, treatment can be intensive. The current first-line options combine different classes of drugs. One approach pairs an immunotherapy drug with a targeted therapy that delivers a cell-killing agent directly to cancer cells. Another combines immunotherapy with platinum-based chemotherapy. A third uses chemotherapy first, followed by immunotherapy as a maintenance step to keep the cancer in check.
For patients healthy enough to tolerate it, platinum-based chemotherapy regimens remain a backbone of treatment. These typically involve cisplatin combined with one or more other drugs. Fitness matters here. Cisplatin is hard on the kidneys, and not every patient can safely receive it. For those who can’t, immunotherapy alone is an option.
Treatment for Metastatic Disease
Stage 4B treatment uses many of the same drug combinations as 4A, but the overarching goal shifts. Cure is rarely realistic once cancer has spread to distant organs. Instead, the aim is to shrink tumors, slow progression, and manage symptoms for as long as possible.
One of the most significant advances in recent years has been a class of drugs called antibody-drug conjugates. These work by attaching a toxic payload to an antibody that homes in on a protein found on bladder cancer cells. In a major clinical trial of 608 patients whose cancer had already progressed through both chemotherapy and immunotherapy, patients receiving this type of drug lived a median of about 13 months compared to 9 months with standard chemotherapy. That roughly four-month difference may sound modest, but for a cancer that had already resisted two lines of treatment, it represented a meaningful gain.
Immunotherapy drugs that block the PD-1 or PD-L1 pathway, proteins cancer cells use to hide from the immune system, are now a standard part of treatment. Several are approved for metastatic bladder cancer, either combined with chemotherapy or used on their own. These drugs don’t work for everyone, but a subset of patients respond well and maintain that response for extended periods.
Genomic Testing and Targeted Therapy
About 15% of muscle-invasive or metastatic bladder cancers carry a specific genetic alteration in a growth-signaling gene called FGFR3. When this alteration is present, a targeted drug that blocks this signal can be effective. This is why tumor genomic testing has become routine for advanced bladder cancer. It identifies patients who may benefit from a treatment that would be useless for the other 85%.
Survival Rates in Context
The numbers most frequently cited come from the SEER database, which tracks cancer outcomes across the United States. For bladder cancer that has spread to regional lymph nodes, the five-year relative survival rate is 40.5%. For distant metastatic disease, it drops to 9.1%. These figures are based on patients diagnosed between 2015 and 2021, which means many were treated before the newest drug combinations became widely available.
Survival statistics also represent averages across all patients, including those who were older, had other serious health conditions, or could not tolerate aggressive treatment. A younger, otherwise healthy person with a strong response to immunotherapy may far outlive the median. Conversely, someone diagnosed with widespread metastases and poor kidney function faces a tougher path. Before platinum-based chemotherapy and immunotherapy became standard, median survival for metastatic bladder cancer was considerably shorter than the 10 to 14 months now typical with current regimens.
Symptom Management and Quality of Life
Because stage 4 bladder cancer often causes pain, urinary problems, and fatigue, symptom management runs alongside cancer-directed treatment from the start. Bone metastases can cause significant pain and fracture risk, so radiation therapy to specific bone sites is common for relief. Urinary obstruction may require a stent or external drainage to protect the kidneys. Weight loss and fatigue are addressed with nutritional support and activity modification.
Palliative care, which focuses entirely on comfort and quality of life, is not the same as hospice and does not mean giving up on treatment. It can be layered on top of chemotherapy and immunotherapy at any point. Studies across many cancer types consistently show that patients who receive palliative care alongside active treatment report better quality of life and, in some cases, live longer than those who don’t.